Recombinant Vaccine Market Size Analysis 2022 with Business Boosting Technologies, Forthcoming Growth Rate, Top Regions, Key Players and Investments Opportunities Forecast to 2028

The global recombinant vaccine market is anticipated to grow at a considerable CAGR during the forecast period 2022-2028. They companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in July 2020, Sanofi and GlaxoSmithKline have collaborated with the U.S Government to supply 100 million doses of their COVID-19 recombinant protein-based vaccine. This collaboration aimed to meet the government's Operation Warp Speed Goal, to ensure the availability of 100 million effective covid-19 vaccine doses in a rapid manner. Moreover, the companies also collaborated with the UK government to supply up to 60 million doses of recombinant protein-based COVID-19 vaccine. Further, the companies also announced the collaboration with global health organizations, businesses, and leaders of governments to speed up the production activities and ensure equitable access to COVID-19 treatments and vaccines.

(Get 15% Discount on Buying this Report)
A full report of Global Recombinant Vaccine Market is available at: https://orionmarketreports.com/recombinant-vaccine-market/95632/

Additionally, in May 2021, Bavarian Nordic A/S has partnered with Dynavax Technologies Corp with an intent to commercialize and distribute the Heplisav-b. Heplisav -b is a recombinant hepatitis b vaccine developed by Dynavax Technologies Corp. In February 2021, the European Commission granted the marketing authorization for Heplisav-b for immunization against hepatitis -b virus infection in individuals of 18 years and above.
Furthermore, in November 2021, The Phillippine Food and Drug Administration granted an emergency use authorization of recombinant nanoparticle protein-based COVID-19 with Matrix-M adjuvant. The vaccine will be manufactured in the Philippines by the Serum Institute of India (SII) under the brand name COVOVAX. Thus, product launches and key collaborations are anticipated to accelerate the growth of the global recombinant vaccine market during the forecast period.

Market Coverage
• The market number available for - 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Route of Administration
o By Disease
o By Distribution Channel

• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World

• Competitive Landscape- GlaxoSmithKline plc, Sanofi S.A., and Merck & Co, Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Recombinant Vaccine Market Report Segment

By Type
• Subunit Vaccine
• Live Attenuated

By Route of Administration
• Oral
• Parenteral

By Disease
• Human Papilloma Virus
• Hepatitis b
• Rotavirus
• Others

By Distribution Channel
• Hospital and Retail Pharmacies
• Government Supplier

Media Contact:

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Us:

Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.